Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint

Journal of Cystic Fibrosis

Volumn 9, Issue 5, 2010, Pages 332-338

  Konstan, M W ^a   Wagener, J S ^b   Yegin, A ^c   Millar, S J ^d   Pasta, D J ^d   VanDevanter, D R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d ICON CLINICAL RESEARCH   (United States)

Author keywords

Rate of decline; Sample size; Study design

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; METHODOLOGY; PRESCHOOL CHILD; PSEUDOMONAS INFECTION; RISK FACTOR; SAMPLING; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; FEASIBILITY STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MIDDLE AGED; PERSONNEL SELECTION; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956925970     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.05.004     Document Type: Article

References (18)

1. Cystic Fibrosis Foundation Patient Registry 2008 Annual Data Report 2009, Cystic Fibrosis Foundation, Bethesda, Maryland.
2. Corey M., Edwards L., Levison H., Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997, 131:809-814.
3. Schluchter M.D., Konstan M.W., Davis P.B. Jointly modeling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002, 21:1271-1287.
4. Konstan M.W., Morgan W.J., Butler S.M., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007, 151:134-139.
5. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
6. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
7. Ren C.L., Pasta D.J., Rasouliyan L., Wagener J.S., Konstan M.W., Morgan W.J. The initiation of inhaled corticosteroid therapy in cystic fibrosis patients is associated with a slower rate of lung function decline. J Pediatr 2008, 153:746-751.
8. Davis P.B., Byard P.J., Konstan M.W. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997, 41:161-165.
9. VanDevanter D.R., Konstan M.W. CF drug developers: victims of our own success. Respir Drug Deliv 2008, 1:11-18.
10. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007, 151:249-254.
11. Murphy T.D., Anbar R.D., Lester L.A., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004, 38:314-320.
12. Elkins M.R., Robinson M., Rose B.R., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
13. Morgan W.J., Butler S.M., Johnson C.A., et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999, 28:231-241.
14. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-88.
15. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
16. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
17. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999, 340:23-30.
18. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.